1
|
Madariaga A, Coleman RL, González Martín A. Novel therapies leading to a new landscape in gynecologic tumors. Int J Gynecol Cancer 2023; 33:321-322. [PMID: 36878568 DOI: 10.1136/ijgc-2023-004318] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/08/2023] Open
Affiliation(s)
- Ainhoa Madariaga
- Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - Robert L Coleman
- Texas Oncology, Sarah Cannon Research Institute, Nashville, Tennessee, USA
| | | |
Collapse
|
2
|
Madariaga A, Sanchez-Bayona R, Herrera FG, Ramirez PT, González Martín A. Outcomes and endpoints of relevance in gynecologic cancer clinical trials. Int J Gynecol Cancer 2023; 33:323-332. [PMID: 36878559 DOI: 10.1136/ijgc-2022-003727] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/08/2023] Open
Abstract
Drug development is paramount to improve outcomes in patients with gynecologic cancers. A randomized clinical trial should measure whether a clinically relevant improvement is detected with the new intervention compared with the standard of care, using reproductible and appropriate endpoints. Clinically meaningful improvements in overall survival and/or quality of life (QoL) are the gold standards to measure benefit of new therapeutic strategies. Alternative endpoints, such as progression-free survival, provide an earlier measure of the effect of the new therapeutic drug, and are not confounded by the effect of subsequent lines of therapy. Yet, its surrogacy with improved overall survival or QoL is unclear in gynecologic malignancies. Of relevance to studies assessing maintenance strategies are other time-to-event endpoints, such as progression-free survival two and time to second subsequent treatment, which provide valuable information on the disease control in the longer term. Translational and biomarker studies are increasingly being incorporated into gynecologic oncology clinical trials, as they may allow understanding of the biology of the disease, resistance mechanisms, and enable a better selection of patients who might benefit from the new therapeutic strategy. Globally, the endpoint selection of a clinical trial will differ according to the type of study, population, disease setting, and type of therapeutic strategy. This review provides an overview of primary and secondary endpoint selection of relevance for gynecologic oncology clinical trials.
Collapse
Affiliation(s)
- Ainhoa Madariaga
- Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain
| | | | - Fernanda G Herrera
- Department of Oncology, Radiation Oncology Service, Centre Hospitalier Universitaire Vaudois CHUV-UNIL, Ludwig Institute for Cancer Research and AGORA Cancer Research Center, Lausanne, Switzerland
| | - Pedro T Ramirez
- Department of Gynecologic Oncology and Reproductive Medicine, MD Anderson Cancer Center, Houston, Texas, USA
| | | |
Collapse
|
3
|
González Martín A, Oza AM, Embleton AC, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Bertrand MA, Beale P, Cervantes A, Kent E, Kaplan RS, Parmar MKB, Scotto N, Perren TJ. Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer. Gynecol Oncol 2019; 152:53-60. [PMID: 30449719 PMCID: PMC6338677 DOI: 10.1016/j.ygyno.2018.08.036] [Citation(s) in RCA: 26] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2018] [Revised: 08/22/2018] [Accepted: 08/26/2018] [Indexed: 01/14/2023]
Abstract
OBJECTIVE In the randomized phase 3 ICON7 trial (ISRCTN91273375), adding bevacizumab to chemotherapy for newly diagnosed ovarian cancer significantly improved progression-free survival (PFS; primary endpoint) but not overall survival (OS; secondary endpoint) in the intent-to-treat (ITT) population. We explored treatment effect according to stage and extent of residual disease. METHODS Patients with stage IIB-IV or high-risk (grade 3/clear-cell) stage I-IIA ovarian cancer were randomized to receive six cycles of carboplatin and paclitaxel either alone or with bevacizumab 7.5 mg/kg every 3 weeks followed by single-agent bevacizumab for 12 further cycles (total duration 12 months). Post hoc exploratory analyses of subgroups defined by stage and extent of residual disease at diagnosis within the stage IIIB-IV population (European indication) was performed. RESULTS The PFS benefit from bevacizumab was seen consistently in all subgroups explored. The PFS hazard ratio was 0.77 (95% confidence interval [CI], 0.59-0.99) in 411 patients with stage IIIB-IV ovarian cancer with no visible residuum and 0.81 (95% CI, 0.69-0.95) in 749 patients with stage IIIB-IV disease and visible residuum. As in the ITT population, no OS difference was detected in any subgroup except the previously described 'high-risk' subgroup. Safety results in analyzed subgroups were consistent with the overall population. CONCLUSIONS Adding bevacizumab to front-line chemotherapy improves PFS irrespective of stage/residual disease. In patients with stage III with >1 cm residuum, stage IV or inoperable disease, this translates into an OS benefit. No OS benefit or detriment was seen in other subgroups explored.
Collapse
Affiliation(s)
| | - Amit M Oza
- Princess Margaret Cancer Centre, University Health Network Toronto, 610 University Avenue, Toronto, ON M5G 2M9, Canada.
| | - Andrew C Embleton
- Medical Research Council Clinical Trials Unit at University College London (UCL), 90 High Holborn, London WC1V 6LJ, UK.
| | - Jacobus Pfisterer
- Gynecologic Oncology Center, Herzog-Friedrich-Str. 21, 24103 Kiel, Germany.
| | | | - Eric Pujade-Lauraine
- Hôpital Hôtel-Dieu, Assistance Publique - Hôpitaux de Paris, 1, Parvis Notre-Dame - Place Jean-Paul II, 75181 Paris CEDEX 04, France.
| | - Gunnar Kristensen
- Department of Gynecologic Oncology and Institute for Cancer Genetics and Informatics, Radiumhospital, Oslo University Hospital, PO Box 4950, Nydalen, N-0424 Oslo, Norway.
| | - Monique A Bertrand
- Western University and London Health Sciences Centre, 800 Commissioners Road East, PO Box 5010, Stn B, London, ON N6A 5W9, Canada.
| | - Philip Beale
- University of Sydney and Royal Prince Alfred Hospital, Level 6, Gloucester House, RPAH, Missenden Road, Camperdown, NSW 2050, Australia.
| | - Andrés Cervantes
- CIBERONC, Biomedical Research Institute INCLIVA, University of Valencia and Hospital Clínico de Valencia, Servicio de Hematología y Oncología Médica, Av. Blasco Ibáñez 17, 46010, Valencia, Spain.
| | - Emma Kent
- Medical Research Council Clinical Trials Unit at University College London (UCL), 90 High Holborn, London WC1V 6LJ, UK.
| | - Richard S Kaplan
- Medical Research Council Clinical Trials Unit at University College London (UCL), 90 High Holborn, London WC1V 6LJ, UK.
| | - Mahesh K B Parmar
- Medical Research Council Clinical Trials Unit at University College London (UCL), 90 High Holborn, London WC1V 6LJ, UK.
| | - Nana Scotto
- F. Hoffmann-La Roche Ltd, Building 1, Grenzacherstrasse 124, CH-4070 Basel, Switzerland.
| | - Timothy J Perren
- Leeds Institute for Cancer Medicine and Pathology, St James's University Hospital, Beckett Street, Leeds LS9 7TF, UK.
| |
Collapse
|
4
|
González Martín A, Oza AM, Embleton AC, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Bertrand MA, Beale P, Cervantes A, Kent E, Kaplan RS, Parmar MKB, Scotto N, Perren TJ. Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer. Gynecol Oncol 2018. [PMID: 30449719 DOI: 10.1016/j.ygyno.2018.08.036] [] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
OBJECTIVE In the randomized phase 3 ICON7 trial (ISRCTN91273375), adding bevacizumab to chemotherapy for newly diagnosed ovarian cancer significantly improved progression-free survival (PFS; primary endpoint) but not overall survival (OS; secondary endpoint) in the intent-to-treat (ITT) population. We explored treatment effect according to stage and extent of residual disease. METHODS Patients with stage IIB-IV or high-risk (grade 3/clear-cell) stage I-IIA ovarian cancer were randomized to receive six cycles of carboplatin and paclitaxel either alone or with bevacizumab 7.5 mg/kg every 3 weeks followed by single-agent bevacizumab for 12 further cycles (total duration 12 months). Post hoc exploratory analyses of subgroups defined by stage and extent of residual disease at diagnosis within the stage IIIB-IV population (European indication) was performed. RESULTS The PFS benefit from bevacizumab was seen consistently in all subgroups explored. The PFS hazard ratio was 0.77 (95% confidence interval [CI], 0.59-0.99) in 411 patients with stage IIIB-IV ovarian cancer with no visible residuum and 0.81 (95% CI, 0.69-0.95) in 749 patients with stage IIIB-IV disease and visible residuum. As in the ITT population, no OS difference was detected in any subgroup except the previously described 'high-risk' subgroup. Safety results in analyzed subgroups were consistent with the overall population. CONCLUSIONS Adding bevacizumab to front-line chemotherapy improves PFS irrespective of stage/residual disease. In patients with stage III with >1 cm residuum, stage IV or inoperable disease, this translates into an OS benefit. No OS benefit or detriment was seen in other subgroups explored.
Collapse
Affiliation(s)
| | - Amit M Oza
- Princess Margaret Cancer Centre, University Health Network Toronto, 610 University Avenue, Toronto, ON M5G 2M9, Canada.
| | - Andrew C Embleton
- Medical Research Council Clinical Trials Unit at University College London (UCL), 90 High Holborn, London WC1V 6LJ, UK.
| | - Jacobus Pfisterer
- Gynecologic Oncology Center, Herzog-Friedrich-Str. 21, 24103 Kiel, Germany.
| | | | - Eric Pujade-Lauraine
- Hôpital Hôtel-Dieu, Assistance Publique - Hôpitaux de Paris, 1, Parvis Notre-Dame - Place Jean-Paul II, 75181 Paris CEDEX 04, France.
| | - Gunnar Kristensen
- Department of Gynecologic Oncology and Institute for Cancer Genetics and Informatics, Radiumhospital, Oslo University Hospital, PO Box 4950, Nydalen, N-0424 Oslo, Norway.
| | - Monique A Bertrand
- Western University and London Health Sciences Centre, 800 Commissioners Road East, PO Box 5010, Stn B, London, ON N6A 5W9, Canada.
| | - Philip Beale
- University of Sydney and Royal Prince Alfred Hospital, Level 6, Gloucester House, RPAH, Missenden Road, Camperdown, NSW 2050, Australia.
| | - Andrés Cervantes
- CIBERONC, Biomedical Research Institute INCLIVA, University of Valencia and Hospital Clínico de Valencia, Servicio de Hematología y Oncología Médica, Av. Blasco Ibáñez 17, 46010, Valencia, Spain.
| | - Emma Kent
- Medical Research Council Clinical Trials Unit at University College London (UCL), 90 High Holborn, London WC1V 6LJ, UK.
| | - Richard S Kaplan
- Medical Research Council Clinical Trials Unit at University College London (UCL), 90 High Holborn, London WC1V 6LJ, UK.
| | - Mahesh K B Parmar
- Medical Research Council Clinical Trials Unit at University College London (UCL), 90 High Holborn, London WC1V 6LJ, UK.
| | - Nana Scotto
- F. Hoffmann-La Roche Ltd, Building 1, Grenzacherstrasse 124, CH-4070 Basel, Switzerland.
| | - Timothy J Perren
- Leeds Institute for Cancer Medicine and Pathology, St James's University Hospital, Beckett Street, Leeds LS9 7TF, UK.
| | | |
Collapse
|
5
|
González Martín A, Oza AM, Embleton AC, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Bertrand MA, Beale P, Cervantes A, Kent E, Kaplan RS, Parmar MKB, Scotto N, Perren TJ. Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer. Gynecol Oncol 2018. [PMID: 30449719 DOI: 10.1016/j.ygyno.2018.08.036]+[] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/30/2022]
Abstract
OBJECTIVE In the randomized phase 3 ICON7 trial (ISRCTN91273375), adding bevacizumab to chemotherapy for newly diagnosed ovarian cancer significantly improved progression-free survival (PFS; primary endpoint) but not overall survival (OS; secondary endpoint) in the intent-to-treat (ITT) population. We explored treatment effect according to stage and extent of residual disease. METHODS Patients with stage IIB-IV or high-risk (grade 3/clear-cell) stage I-IIA ovarian cancer were randomized to receive six cycles of carboplatin and paclitaxel either alone or with bevacizumab 7.5 mg/kg every 3 weeks followed by single-agent bevacizumab for 12 further cycles (total duration 12 months). Post hoc exploratory analyses of subgroups defined by stage and extent of residual disease at diagnosis within the stage IIIB-IV population (European indication) was performed. RESULTS The PFS benefit from bevacizumab was seen consistently in all subgroups explored. The PFS hazard ratio was 0.77 (95% confidence interval [CI], 0.59-0.99) in 411 patients with stage IIIB-IV ovarian cancer with no visible residuum and 0.81 (95% CI, 0.69-0.95) in 749 patients with stage IIIB-IV disease and visible residuum. As in the ITT population, no OS difference was detected in any subgroup except the previously described 'high-risk' subgroup. Safety results in analyzed subgroups were consistent with the overall population. CONCLUSIONS Adding bevacizumab to front-line chemotherapy improves PFS irrespective of stage/residual disease. In patients with stage III with >1 cm residuum, stage IV or inoperable disease, this translates into an OS benefit. No OS benefit or detriment was seen in other subgroups explored.
Collapse
Affiliation(s)
| | - Amit M Oza
- Princess Margaret Cancer Centre, University Health Network Toronto, 610 University Avenue, Toronto, ON M5G 2M9, Canada.
| | - Andrew C Embleton
- Medical Research Council Clinical Trials Unit at University College London (UCL), 90 High Holborn, London WC1V 6LJ, UK.
| | - Jacobus Pfisterer
- Gynecologic Oncology Center, Herzog-Friedrich-Str. 21, 24103 Kiel, Germany.
| | | | - Eric Pujade-Lauraine
- Hôpital Hôtel-Dieu, Assistance Publique - Hôpitaux de Paris, 1, Parvis Notre-Dame - Place Jean-Paul II, 75181 Paris CEDEX 04, France.
| | - Gunnar Kristensen
- Department of Gynecologic Oncology and Institute for Cancer Genetics and Informatics, Radiumhospital, Oslo University Hospital, PO Box 4950, Nydalen, N-0424 Oslo, Norway.
| | - Monique A Bertrand
- Western University and London Health Sciences Centre, 800 Commissioners Road East, PO Box 5010, Stn B, London, ON N6A 5W9, Canada.
| | - Philip Beale
- University of Sydney and Royal Prince Alfred Hospital, Level 6, Gloucester House, RPAH, Missenden Road, Camperdown, NSW 2050, Australia.
| | - Andrés Cervantes
- CIBERONC, Biomedical Research Institute INCLIVA, University of Valencia and Hospital Clínico de Valencia, Servicio de Hematología y Oncología Médica, Av. Blasco Ibáñez 17, 46010, Valencia, Spain.
| | - Emma Kent
- Medical Research Council Clinical Trials Unit at University College London (UCL), 90 High Holborn, London WC1V 6LJ, UK.
| | - Richard S Kaplan
- Medical Research Council Clinical Trials Unit at University College London (UCL), 90 High Holborn, London WC1V 6LJ, UK.
| | - Mahesh K B Parmar
- Medical Research Council Clinical Trials Unit at University College London (UCL), 90 High Holborn, London WC1V 6LJ, UK.
| | - Nana Scotto
- F. Hoffmann-La Roche Ltd, Building 1, Grenzacherstrasse 124, CH-4070 Basel, Switzerland.
| | - Timothy J Perren
- Leeds Institute for Cancer Medicine and Pathology, St James's University Hospital, Beckett Street, Leeds LS9 7TF, UK.
| | | |
Collapse
|
6
|
González Martín A. Progress in PARP inhibitors beyond BRCA mutant recurrent ovarian cancer? Lancet Oncol 2016; 18:8-9. [PMID: 27908593 DOI: 10.1016/s1470-2045(16)30621-0] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2016] [Revised: 11/07/2016] [Accepted: 11/07/2016] [Indexed: 11/29/2022]
|
7
|
Glasspool RM, González Martín A, Millan D, Lorusso D, Åvall-Lundqvist E, Hurteau JA, Davis A, Hilpert F, Kim JW, Alexandre J, Ledermann JA. Gynecologic Cancer InterGroup (GCIG) consensus review for squamous cell carcinoma of the ovary. Int J Gynecol Cancer 2014; 24:S26-9. [PMID: 25126954 DOI: 10.1097/igc.0000000000000209] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
Squamous cell carcinoma of the ovary is a rare complication of mature cystic teratoma. The epidemiology, pathology, diagnosis, and management of this rare tumor are reviewed. Clinical characteristics, preoperative imaging, and tumor markers may help to predict malignancy preoperatively. Complete cytoreduction should be the aim of surgery. The prognosis for stage 1A disease is good, but for women with advanced or recurrent disease, it is very poor and has not improved in recent years. At present, there are insufficient data to provide clear guidance on the optimal management strategy for advanced disease, and there is a need to gain an understanding of the biology and to develop novel effective therapies. This will require coordinated international collaboration.
Collapse
Affiliation(s)
- Rosalind M Glasspool
- *Beatson West of Scotland Cancer Centre, Glasgow, UK (SGCTG); †Medical Oncology Department, MD Anderson Cancer Centre, Madrid, Spain (GEICO); ‡Southern General Hospital, Glasgow, UK (SGCTG); §Gynecologic Oncology Unit, Fondazione IRCCS National Cancer institute of Milan (MITO), Milan, Italy; ‖Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden (NSGO); ¶Division of Gynecologic Oncology, NorthShore University Health System, University of Chicago Pritzker School of Medicine, Evanston, IL (GOG); #The Canberra Hospital, Canberra, Australia (ANZGOG); **University Hospital of Schleswig-Holstein Campus, Kiel, Germany (AGO); ††Department of Obstectrics and Gynecology, Seoul National University College of Medicine, Seoul, Republic of Korea (KGOG); ‡‡Medical Oncology, Cochin-Hôtel Dieu, Paris Descartes University, Paris, France (GINECO); and §§UCL Cancer Institute, London, UK (NCRI/MRC)
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
González Martín A, Bratos R, Márquez R, Alonso S, Chiva L. Bevacizumab as front-line treatment for newly diagnosed epithelial cancer. Expert Rev Anticancer Ther 2014; 13:123-9. [DOI: 10.1586/era.12.165] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
9
|
|
10
|
Guerra Alía EM, Garrido López P, Pachón Olmos V, Medina Martínez J, González Martín A, Vaz Salgado MA. [Secondary hypopituitarism due to hypothalamic metastasis from small cell lung cancer]. ACTA ACUST UNITED AC 2009; 56:201-4. [PMID: 19627737 DOI: 10.1016/s1575-0922(09)70985-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2008] [Accepted: 03/23/2009] [Indexed: 11/25/2022]
Abstract
Parasellar and hypothalamic metastases are uncommon. Their principal clinical manifestation is diabetes insipidus. Associated hypopituitarism is very rare. We report the case of a 54-year-old man with small cell lung cancer and hypopituitarism. A brain magnetic resonance imaging scan revealed a mass in the anterior region of the third ventricle with no clear etiology. The patient began chemotherapy treatment and the mass disappeared, which confirmed the diagnosis of secondary hypopituitarism caused by hypothalamic metastasis from small cell lung cancer.
Collapse
|
11
|
Malet G, Martín AG, Orzáez M, Vicent MJ, Masip I, Sanclimens G, Ferrer-Montiel A, Mingarro I, Messeguer A, Fearnhead HO, Pérez-Payá E. Small molecule inhibitors of Apaf-1-related caspase- 3/-9 activation that control mitochondrial-dependent apoptosis. Cell Death Differ 2005; 13:1523-32. [PMID: 16341125 DOI: 10.1038/sj.cdd.4401828] [Citation(s) in RCA: 63] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
Apoptosis is a biological process relevant to human disease states that is strongly regulated through protein-protein complex formation. These complexes represent interesting points of chemical intervention for the development of molecules that could modulate cellular apoptosis. The apoptosome is a holoenzyme multiprotein complex formed by cytochrome c-activated Apaf-1 (apoptotic protease-activating factor), dATP and procaspase-9 that link mitochondria disfunction with activation of the effector caspases and in turn is of interest for the development of apoptotic modulators. In the present study we describe the identification of compounds that inhibit the apoptosome-mediated activation of procaspase-9 from the screening of a diversity-oriented chemical library. The active compounds rescued from the library were chemically optimised to obtain molecules that bind to both recombinant and human endogenous Apaf-1 in a cytochrome c-noncompetitive mechanism that inhibits the recruitment of procaspase-9 by the apoptosome. These newly identified Apaf-1 ligands decrease the apoptotic phenotype in mitochondrial-mediated models of cellular apoptosis.
Collapse
Affiliation(s)
- G Malet
- Department of Biochemistry and Molecular Biology, Universitat de València, E-46100 Burjassot, València, Spain
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Laín de Lera T, Folgueira L, Martín AG, Dargemont C, Pedraza MA, Bermejo M, Bonay P, Fresno M, Alcami J. Expression of IkappaBalpha in the nucleus of human peripheral blood T lymphocytes. Oncogene 1999; 18:1581-8. [PMID: 10102628 DOI: 10.1038/sj.onc.1202455] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
According to current models the inhibitory capacity of I(kappa)B(alpha) would be mediated through the retention of Rel/NF-kappaB proteins in the cytosol. However, I(kappa)B(alpha) has also been detected in the nucleus of cell lines and when overexpressed by transient transfection. To gain better insight into the potential role of nuclear I(kappa)B(alpha) in a physiological context we have analysed its presence in the nucleus of human peripheral blood T lymphocytes (PBL). We demonstrate the nuclear localization of I(kappa)B(alpha) in PBL by different techniques: Western blot, indirect immunofluorescence and electron microscopy. Low levels of nuclear I(kappa)B(alpha) were detected in resting cells whereas a superinduction was obtained after PMA activation. The nuclear pool of I(kappa)B(alpha) showed a higher stability than cytosolic I(kappa)B(alpha) and was partially independent of the resynthesis of the protein. Unexpectedly, the presence of nuclear I(kappa)B(alpha) did not inhibit NF-kappaB binding to DNA and this phenomenon was not due to the presence of IkappaBbeta at the nuclear level. Immunoprecipitation experiments failed to demonstrate an association between nuclear I(kappa)B(alpha) and NF-kappaB proteins. Our results demonstrate that in resting and PMA-activated human PBL, I(kappa)B(alpha) is present in the nucleus in an apparently inactive form unable to disrupt NF-kappaB binding from DNA.
Collapse
Affiliation(s)
- T Laín de Lera
- Servicio de Microbiología, Centro de Investigación, Hospital 12 de Octubre, Madrid, Spain
| | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Martín AG. [Debate on general internal medicine]. Med Clin (Barc) 1996; 106:276-7. [PMID: 8667680] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
|